Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily.

In our last episode of Health Update, my M-protein level was starting to rise, indicating that the Revlimid was losing effectiveness and the multiple myeloma was staging a comeback. This is normal and expected after two years. When it got above 1.0, it would be time to switch to a second-line treatment. In the end, I got nearly three years out of the Revlimid, but the time has now come to move on:

The new treatment will consist of an oral version of my old friend Velcade teamed up with Darzalex, a monoclonal antibody that’s one of the slew of new treatments that have been approved over the past few years. I will also once again be taking the evil dex, a sleep killer marketed as a corticosteroid. During my last round of dex, I used my treatment nights to write a 40-page tutorial on special and general relativity. I can’t really say why I did that, but I’m sure it would have been a publishing sensation if I had ever published it.

Anyway, the new treatment will start in a week or so. It’s once a week for two months, then once every two weeks for two months, and then once a month. The total length of time depends on how I respond. Once the M-proteins are back under control, I’ll begin a maintenance routine which will hopefully last a couple of years. Keep your fingers crossed.

Keep us relentless, independent, and free to read.

For 50 years, Mother Jones has offered honest, investigative reporting you can rely on:

    • Relentless in the pursuit of truth, unafraid to hold the powerful to account

    • Independent from influence or agenda from oligarchs and corporations

    • Freely accessible to every reader, never behind a paywall

But we can’t do any of this without you. Reader support powers our newsroom to stay nimble and fearless, ready for whatever story comes next. If you can, make a donation today.

Keep us relentless, independent, and free to read.

For 50 years, Mother Jones has offered honest, investigative reporting you can rely on:

    • Relentless in the pursuit of truth, unafraid to hold the powerful to account

    • Independent from influence or agenda from oligarchs and corporations

    • Freely accessible to every reader, never behind a paywall

But we can’t do any of this without you. Reader support powers our newsroom to stay nimble and fearless, ready for whatever story comes next. If you can, make a donation today.

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate